The CANTOS (2017) trial demonstrated that the IL-1β inhibitor Canakinumab can significantly reduce the rate of recurrent cardiovascular events in atherosclerotic patients independent of lipid-lowering therapy, underscoring the relevance of inflammation and cytokine inhibition in atherosclerosis and subsequent IHD [6, 79]. This evidence concerns the gene IL1B and myocardial ischemia.